• Sanofi iNext

The industrial partner, Sanofi (vaccins branch), invites academic labs from the Institut Pasteur to submit groundbreaking proposals in one or both of the following fields:

• Next-Gen approaches to counter aging related cellular and tissue dysfunction
  Including approaches to restore cellular and tissue function, counteract age-related immune decline, prevent chronic inflammation, and retain vaccine response.
   
• Paradigm shifting strategies for targeted delivery of large molecules and nucleic acids
  Including proteins (antigenic and therapeutic) and genetic material across biological barriers (skin, mucosa, BBB, intracellular/intranuclear).

Key dates

• All submissions must be validates by the DARRI prior to submission: sanofiinextdarri25@pasteur.fr before January 22, 2026
• Pre-Proposal Evaluation until mid-February 2026
• Invitation for selected Full Proposal is available until March 31,2026
• The final pitching showcase will be held virtually in June 2026 (exact date TBD). The invited finalists will have a unique opportunity to pitch in front of the key decision makers in Sanofi
• The results will then be announced two weeks after the Pitching Event!

Essential Characteristics

• Up to USD $500,000 per project (inclusive of all costs)  
• Funds an 18-months journey

More information

Contact: sanofiinextdarri25@pasteur.fr  
 

• CSL Behring Research Acceleration Initiative (RAI) 2026  

CSL is a leading global biotechnology company focused on developing and delivering innovative biotherapies.
The Research Acceleration Initiative (RAI) supports innovative research projects that address unmet medical needs and align with CSL Behring’s therapeutic areas.

Key dates

• Opening of the call: January 5, 2026
• If you would like the possibility to participate in detailed and targeted information sessions with CSL Behring, please contact the DARRI by Monday, February 2
• Please send your 500-word non-confidential abstract to the DARRI (shauna.katz@pasteur.fr) by Monday, February 16
• Full application deadline (non-confidential): April 23, 2026
• Presentations of shortlisted projects: Mid-june 2026
• Notification of intention to fund successful projects: September 2026

Essential Characteristics

• Funding amount: up to $400k
• Project duration: 24 months  
• Non-dilutive funding to accelerate early-stage scientific innovations  
• A funding agreement will be negotiated for each project which may gran CSL certain rights of interest to the program results 

Eligibility Criteria

• Focused on a novel target or therapeutic candidate within CSL’s following therapeutic areas of interest : Immunoglobulins, hematology, cariod-renal, transplant & immunology
• Work within an organization registered with CSL  

Benefits of a partnership with CSL

• Access to a dedictaed CSL scientific expert for feedback and guidance on your project  
• Potential to co-author publications with CSL  
• Early collaborations with high quality academic and biotech partners are key to building a sustainable pipeline  
• The research organization will generally own the results of the project, and CSL will be granted an exclusive option to negotiate an exclusive worldwide license

How to apply  

• If you are interested, please contact shauna.katz@pasteur.fr (contact for the CSL Behring RAI)
• All submissions will be centralized via the CSL Behring RAI contact point
• All 500-word non-confidential abstracts must be validates by the DARRI prior to submission

More information

For any question, send an email to shauna.katz@pasteur.fr